Compare GameStop Corp. (GME) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Incyte Corporation — how do they compare? GameStop Corp. trades at $22.3 (market cap $9.99B), while Incyte Corporation trades at $116.13 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 2.3× GameStop Corp.'s market cap, and Incyte Corporation is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| GME | INCY | |
|---|---|---|
Market Cap | $9.99B | $22.99B |
Sector | Consumer Cyclical | Health |
52-Week High | $27.69 | $118.52 |
52-Week Low | $19.94 | $67.38 |
Enterprise Value | $5.96B | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $22.36, down 0.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue declined to $3.82 billion in 2025, but net income improved to $131.3 million, reflecting a profit margin of 3.43%. Recent developments include a partnership with Uber Eats and ongoing efforts to acquire eBay, as announced in Business Wire on June 26, 2026.
The outlook is mixed, with positive EBITDA guidance above $600 million for fiscal 2026 offering upside potential, but risks include revenue declines and dependence on physical media amid Sony's shift away from discs. Analyst sentiment is cautious, with only 16.67% buy ratings, suggesting limited near-term conviction despite operational improvements.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
